Partnerships
At Exxel Pharma, we recognize that strategic partnerships are essential to accelerating drug development and delivering innovative therapies to patients. By collaborating with academic researchers, biotech companies and industry leaders, we can enhance scientific insights and optimize scientific advancements. We welcome partnerships that share our commitment to advancing breakthrough treatments for neuronal hypersensitivity and neurological disorders.
UC Irvine
We are working closely with Professor Piomelli’s laboratory at UC Irvine. The collaboration is focused on preclinical and non-GLP development activities, including testing EX937, EX14280 and EX14663 in different animal models of human disease. One goal of this work is to support additional clinical indications for the Company’s two drugs.
Our Programs
EX937
EX937 is an innovative small molecule being developed for the treatment of refractory chronic cough, a condition that affects approximately 10% of the global population. Leveraging a novel and differentiated approach, by peripherally inhibiting the FAAH enzyme, EX937 has demonstrated marked efficacy and favorable safety in preclinical models.
EX14280 and EX14663
These globally active FAAH inhibitors leverage a chemical scaffold similar to EX937 to achieve body-wide enhancement of anandamide-mediated signaling. Substantial preclinical and clinical data with these and other FAAH inhibitors indicate potential usefulness in the treatment of Social Anxiety Disorder and Autism Spectrum Disorder.